Cargando…
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM) levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within these low levels, CLL with relatively high sIgM (CLL(high)) progresses more rapidly than CLL with low sIgM (CLL(low)). During ibru...
Autores principales: | Chiodin, Giorgia, Drennan, Samantha, Martino, Enrica A., Ondrisova, Laura, Henderson, Isla, del Rio, Luis, Tracy, Ian, D’Avola, Annalisa, Parker, Helen, Bonfiglio, Silvia, Scarfò, Lydia, Sutton, Lesley-Ann, Strefford, Jonathan C., Forster, Jade, Brake, Oliver, Potter, Kathleen N., Sale, Benjamin, Lanham, Stuart, Mraz, Marek, Ghia, Paolo, Stevenson, Freda K., Forconi, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631698/ https://www.ncbi.nlm.nih.gov/pubmed/35640238 http://dx.doi.org/10.1182/bloodadvances.2021006659 |
Ejemplares similares
-
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023) -
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022) -
Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022) -
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021) -
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)